Lupin acquires Symbiomix to strengthen women’s health specialty business


Lupin acquires Symbiomix Therapeutics : Generics pharma company Lupin based in Mumbai has announced the acquisition of Symbiomix Therapeutics through its US subsidiary in a $150 million deal to grow its women’s health specialty business further.

Symbiomix Therapeutics, which was established in 2012 is headquartered in Newark, New Jersey and was backed by three healthcare venture capital firms OrbiMed, F-Prime Capital Partners and HBM Partner.

The pharma startup company develops therapies for gynecologic infections which can cause serious health implications.

Lupin acquisition of Symbiomix Therapeutics adds the latter’s lead candidate Solosec (secnidazole) oral granules to its portfolio.

Representation Photo courtesy : adamr and

A 5-nitroimidazole antimicrobial agent, Solosec has the FDA approval for bacterial vaginosis treatment in adult women.

See also  Ajanta Pharma secures FDA approval for Topiramate Capsules, eyes 2026 market launch

Solosec FDA approval was based on results of different studies that included two pivotal trials in bacterial vaginosis as well as an open label safety trial which demonstrated efficacy for 2gm single-dose of the drug.

After its FDA approval, Solosec became the first and only single dose oral treatment for bacterial vaginosis treatment. Bacterial vaginosis  annually affecting

See also  AMETEK closes $1.9bn MedTech deal to acquire Paragon Medical

Around 21 million women in the United States, between 14 and 49 years of age, are affected by bacterial vaginosis, making it a very common gynecologic infection in the country.

Commenting on Lupin acquisition of Symbiomix Therapeutics, Lupin CEO Vinita Gupta said: “We are delighted to complete the acquisition of Symbiomix and its Solosec brand, which immediately expands Lupin’s US women’s health specialty business into the highly-complementary gynecological infection sector.

See also  Tata Consultancy Services to help Keysight Technologies in IT transformation

“This transaction is an important milestone in the evolution of our Specialty business and gives Lupin a new therapeutic to bring to obstetricians and gynecologists to treat a serious health condition they see frequently in their practices.”

Solosec is expected to be launched commercially in the United States in mid-2018 according to its new owner Lupin.

The bacterial vaginosis drug Solosec will add to Methergine (methylergonovine) tablets, considered as the anchor of the branded women’s health specialty business of Lupin.

For more pharma industry news, keep following

Share This